FORCE(USA) has compiled resources and information to help people make informed decisions and receive support.
People diagnosed with Lynch syndrome have an increased risk for colorectal, endometrial and other cancers. Options are available for cancer treatment, screening and prevention for people with Lynch syndrome.
https://www.facingourrisk.org/portal/people-with-lynch-syndrome
While there is no diet or workout plan that can cure or prevent cancer, research has shown that a change in eating habits could improve outcomes….
https://www.curetoday.com/view/eat-your-veggies-diet-plays-a-role-in-cancer-occurrence-and-outcomes
Cumulative Lifetime risks of cancer in Lynch Syndrome
Endometrial: Up to 57%
Ovarian: Up to 17%
Identifying patients with Lynch syndrome is clinically important because these patients have up to 80 percent lifetime risk of colorectal cancer and up to 60 percent lifetime risk of endometrial cancer.
These patients also have an increased risk for other primary cancers including gastric, ovarian, small bowel, urothelial (ureter, renal pelvis), biliary tract, pancreatic, brain (glioblastoma), sebaceous gland adenomas, and keratoacanthomas.
Individuals found to have a deleterious Lynch syndrome mutation are at increased cancer risk with the greatest risk of colorectal and endometrial cancers, followed by gastric and ovarian cancers. Fortunately, there are risk management guidelines for carriers of Lynch syndrome which are associated with a decrease in cancer-related deaths.
Depression is highly prevalent in those diagnosed with cancer and is also associated with poorer prognostic outcomes. Mindfulness-based interventions are effective in reducing depressive symptoms and improving quality of life in patients with cancer. The objective of this review was to investigate whether mindfulness practices can improve survival and, if so, what mechanisms of action may contribute to these outcomes.
https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21733
Recently, an appreciation of the mechanism of carcinogenesis in LS-associated cancers has contributed to the development of novel therapeutic and diagnostic approaches, with a gene-specific approach to disease management, with potential cancer-preventing vaccines in development. An adaptive approach to surgical or oncological management of LS-related cancers may be considered, including an important role for novel checkpoint inhibitor immunotherapy in locally advanced or metastatic disease. Therefore, a personalised approach to lifelong gene-specific management for people with LS provides many opportunities for cancer prevention and treatment which we outline in this review.
https://fg.bmj.com/content/early/2022/06/01/flgastro-2022-102123
A genetic mutation like Lynch syndrome is not a guarantee that you will develop cancer, but it gives you an increased risk that you will be diagnosed with certain cancers in your lifetime.
The report describes a set of consequential recommendations for accelerating cancer research to achieve the ambitious goal of making a decade’s worth of cancer research progress in five years and to bring the most promising science and clinical developments to all cancer patients in the near term. https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/blue-ribbon-panel-report-2016.pdf
G. Prevention and Early Detection: Implementation of Evidence-Based Approaches: “Currently, there is a need for nationwide efforts to identify individuals with hereditary cancer syndromes, and to determine and implement optimal intervention strategies, such as earlier cancer screenings, that would reduce the risk of developing malignant disease. For example, in the case of LS, which leads to increased risk of colorectal and endometrial cancers as well as other malignancies, tumor testing is recommended for all individuals with CRC; however, fewer than 5% receive this screening, representing a missed opportunity to identify individuals and family members who may have inherited a substantially higher cancer risk.“
Lynch Syndrome Ireland 